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Edited by Barry HalliwellAbstract There are two diﬀerent types of Alzheimers disease,
familiar Alzheimers disease (FAD) and Sporadic Alzheimers
disease (SAD), and the origin of the disease could be diﬀerent
in both familial and sporadic cases. In terms of FAD, mutations
in three diﬀerent genes are likely to promote the onset of the dis-
ease whereas for SAD, diﬀerent risk factors might be involved.
Nevertheless, downstream of the initial causes of the disease
some common factors may be involved. In this review, rather
than the diﬀerences, we have focused on some of the common fea-
tures shared by Alzheimers patients, irrespective of the origin of
their disorder. Among these common features, at the molecular
level, the activation of the protein kinase GSK3 may be relevant.
 2008 Federation of European Biochemical Societies.
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The autopsy of an Alzheimers disease (AD) patient indi-
cates that a huge amount of cell death occurs in diﬀerent re-
gions of the brain that is associated with the presence of two
aberrant structures: senile plaques (SP), composed by amyloid
peptide, and neuroﬁbrillary tangles (NFT), which main com-
ponent is tau protein. This is the ﬁnal picture of the disease,
but what happens in the patients brain that provokes the for-
mation of these aberrant structures and cell death is not prop-
erly known. At present, there are some hypotheses that try to
explain why neuron dies, and how SP and NFT accumulate in
the diﬀerent types of AD such as the familial and sporadic
types. Although, there are diﬀerences between these two diﬀer-
ent types of AD, we will concentrate here on some of the com-
mon features. Indeed, we will mainly discuss the role of the
protein kinase glycogen synthase kinase 3 (GSK3) in the diﬀer-
ent types of this disease.2. GSK3 and its regulation
GSK3 is a protein kinase encoded, in mammals, by two
genes gsk3a and b. The proteins expressed by these genes,*Corresponding author. Fax: +34 91 196 44 20.
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doi:10.1016/j.febslet.2008.10.026mainly diﬀer at their N terminal regions [1]. It is assumed that
GSK3 is constitutively active in a cell and that it could be neg-
atively regulated by phosphorylation at its N terminal region
[2]. This phosphorylation may be regulated by insulin, through
the activation of Akt [3]. On the other hand, GSK3 activity
could be regulated by wnt proteins. GSK3 is present in a poly-
protein complex formed by axin, APC and b-catenin together
with GSK3 [4]. In the presence of wnt proteins this complex is
disrupted and GSK3 activity inhibited [4].
Once GSK3 is activated it may modify some substrates,
including the amyloid peptide precursor protein, mainly by
GSK3a [5], and tau protein mainly by GSK3b [6,7]. The mod-
iﬁcation of these substrates and others like b-catenin [4] or Bax
[8] could result in neurodegeneration. Tau protein is also sub-
strate for other kinases like cdk5 [9–11], MARK [12] or p38
[13,14], among other ones, but in this review, we will focus
on its modiﬁcation by GSK3. For further reading or tau phos-
phorylation and its inhibition we suggest the excellent review
quoted in Ref. [15].3. Familial Alzheimer disease
One particular class of AD, familial AD (FAD), is associ-
ated with mutations in the app, ps1 and ps2 genes [16] respon-
sible for the expression of the APP, PS-1 and PS-2 proteins.
APP is the protein precursor of the amyloid peptide (Ab),
the main component of SP, whereas PS-1/PS-2 are the catalytic
components of a protein complex that displays gamma secre-
tase (proteolytic) activity [17,18]. Signiﬁcantly, cleavage of
APP by beta (BACE-1) and gamma secretases yields the beta
amyloid peptide [16]. Mutations of APP that result in AD
facilitate its cleavage to Ab. In addition, mutations in PS-1/
PS-2 may produce a gain of (c secretase) activity that may also
facilitate the production of Ab [19]. However, no mutations
have been found in the gene expressing BACE-1. Alzheimers
disease is a form of senile dementia and thus, aging is one of
the principal risk factors associated with this disease. Since
b-secretase activity in the brain increases with age, in relation
to conditions of oxidative stress [20–22], at the ages at which
b-secretase activity augments, any additional increase in
c-secretase due to mutations will also augment Ab production.
This is the basis of the Ab cascade hypothesis [19] in which Ab
formation is the ﬁrst step in the initiation of the disease, lead-
ing to the formation of senile plaques (aggregates of Ab) and,
afterwards, the hyperphosphorylation of tau, by kinases likeublished by Elsevier B.V. All rights reserved.
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protein present in NFT.
The activity of GSK3b increases through deregulation of the
insulin and wnt pathways. Indeed, in its oligomerized form Ab
binds to frizzled, the receptor of wnt, preventing wnt from
downregulating GSK3 [23]. On the other hand, Ab is thought
to act as an antagonist of the insulin receptor [24–27], its pres-
ence augmenting GSK3 activity. Indeed, chronic exposure of
mice to Ab produced a down regulation of Akt phosphoryla-
tion [28] that in turn, provokes GSK3 activation. GSK3 may
promote tau phosphorylation, and it has been suggested that
phosphotau can be assembled into ﬁlaments similar to those
that make up the NFT [29]. In addition, Ab aggregates may
reactivate microglia inducing associated inﬂammatory pro-
cesses [30]. Thus, the Ab cascade hypothesis suggests that the
ﬁrst step in AD development could be the formation of Ab
oligomers. This event would explain, in a rather general way,
how SP and NFT form together, as well as the appearance
of others features found in the brain of Alzheimers disease pa-
tients, such as events associated with inﬂammation.
It is signiﬁcant that the development of the disease is more
closely related to neuron death or the appearance of NFT than
to the development of SP [31]. The tau and the disease pathol-
ogy are thought to commence in the entorhinal/hippocampal
region [32] and, from there, it spreads before it ﬁnally aﬀects
the diﬀerent cortical regions where many SP can ultimately
be found. At earlier stages (in the hippocampus), there is no
evidence of amyloid pathology even though NFT can be ob-
served. Curiously, in transgenic mouse models that are thought
to mimic amyloid or tau pathologies, it seems that cortical neu-
rons could be more sensitive to the amyloid pathology than
hippocampal neurons, whereas the opposite could occur in
tau pathologies [33]. However, the amyloid pathology appears
earlier than the tau pathology in the cortex [32]. Thus, it is not
clear whether the ﬁrst steps involve the appearance of beta
amyloid peptide aggregates, at least in the entorhinal cortex–
hippocampal region. This issue might be clariﬁed by taking
into account the appearance of smaller beta peptide oligomers
[34], which might be present but less easy to visualize in that
region. Alternatively, since the most prominent FAD is that
provoked by the presence mutations in PS-1, the pathological
consequences of these PS-1 mutations could be unrelated to
Ab formation in some cases, and more directly related to some
other aberrant PS-1 activity. Indeed, it has been suggested that
PS-1 activates PI3 kinase, an enzyme that inhibits GSK3 activ-
ity [35], and that mutated PS-1 fails to inhibit GSK3 [36]. Such
alterations might promote GSK3 activity in regions like the
hippocampus and this active GSK3 may then phosphorylate
tau protein, causing its accumulation in NFT.4. Sporadic Alzheimers disease
Several risk factors have been associated with sporadic AD,
the most prevalent being aging and the presence of speciﬁc
ApoE isoforms [37]. In addition, oxidative damage has long
been related to aging [38], and it has been proposed as a pri-
mary cause for the initiation of the AD pathology [39,40].
LRP6 is one of the cell receptors for ApoE and it acts as a
co-receptor in the wnt pathway [41,42]. The risk of expressing
a speciﬁc ApoE isoform may be related with GSK3 inactiva-tion and indeed, a common genetic variant of LRP6 was re-
cently associated with late onset AD [43]. One possible
consequence of the appearance of this variant, that should
be tested, is the activation of GSK3 and the ensuing phosphor-
ylation of the tau protein. Little is known about the molecular
mechanisms underlying Ab generation in sporadic AD, but
there are some indications that the activation of beta secretase
might be involved. It is known that oxidative stress increases
beta secretase activity [22] and it has recently been reported
that the loss of a microRNA cluster (miR-29 ab-1), or of other
micro RNAs, is correlated with an increased BACE1 expres-
sion and of sporadic AD [44,45]. In addition, a non-coding
antisense RNA for BACE1 may stabilize BACE mRNA,
thereby increasing the amount of BACE1 protein available
[46]. The increase in b secretase will facilitate Ab production,
which together with a deﬁciency in Ab clearance (possibly
due to the presence of a speciﬁc ApoE isoform) will result in
the appearance of Ab aggregates such as senile plaques. In-
deed, ApoE has been implicated in Ab clearance [47], whereby
ApoE stimulates the degradation of soluble Ab and the pres-
ence of ApoE4 isoforms makes this process less eﬀective [48].
About the role of GSK3 in the regulation of the production
of beta amyloid peptide, it was indicated that GSK3 (mainly
GSK3a) regulates APP cleavage and, concomitantly, the pro-
duction of Ab [5]. About cdk5 and Ab, has been shown a tran-
scriptional regulation of BACE by cdk5 that leads to enhance
amyloidogenic processing [49].5. Oxidative stress and Alzheimer disease
Oxidative stress has also been proposed to participate in the
initiation of sporadic AD. Indeed, like the amyloid cascade
hypothesis [19] to explain the onset of FAD, the oxidation
damage hypothesis [40,50,51] oﬀers an attractive explanation
of SAD based on the premise that oxidative stress precedes
SP and NFT formation in AD [40]. Oxidative stress is deﬁned
as the imbalance between biochemical processes leading to the
production of reactive oxygen species (ROS) and those respon-
sible for their removal [52]. Neurons from the central nervous
system (CNS) are particularly vulnerable to oxidative insults
due to their high rate of oxygen consumption.
The generation of ROS can be modulated by the presence
of certain metals, like iron, that might accumulate in the
brain with age [53]. In addition, metal-catalyzed oxidation
of Ab induces its aggregation [54]. As previously indicated,
oxidative stress may also provoke an increase in BACE1
activity [21,22], facilitating the formation of Ab [55]. In addi-
tion, hydrogen peroxidase can activate c-secretase [56] and
indeed, c-secretase may play a role in the oxidative-stress-in-
duced BACE1 expression in AD [57]. Alternatively, oxidative
stress could produce the oxidation of polyunsaturated fatty
acids yielding products like the aldehyde hydroxynonenal
(HNE) [58,59]. It has been proposed that 4-hydroxynonenal
(HNE), produced as a result of lipid peroxidation, could
be suﬃcient to induce an AD like pathology in mice [51].
HNE binds to tau protein inducing a conformational change,
that is deﬁned by the appearance of the Alz-50 epitope found
in the aggregated tau present in the brain of AD patients
[60]. HNE also facilitates the formation of tau aggregates
‘‘in vitro’’ [61].
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tion. Insulin (or IGF-1) has been shown to protect against neu-
ral oxidative stress [62] and thus, when oxidative stress
develops in conjunction with a decrease in the availability of
these growth factors, activation of GSK3 will be provoked.
On the other hand, the association of aging, the most impor-
tant risk factor for Alzheimer disease, with oxidative stress is
probably associated with impaired mitochondrial activities
[63]. Defects in mitochondrial complex I facilitate the forma-
tion of oxidated ubiquinone (coenzyme Q), and this compound
may favor the formation of tau aggregates [64]. In addition,
tau hyperphosphorylation occurs in mice with reduced levels
of superoxide dismutase and that are therefore susceptible to
an increase in oxidative damage [65]. Defects in the mitochon-
drial complex IV also contribute to oxidative stress and could
result in the accumulation of Ab, possibly due to beta secretase
activity [22,63].
By contrast, an increase in GSK3 activity could inhibit the
antioxidant cell response through the phosphorylation of the
Nrf2 transcription factor [66]. It can not be overlooked that
phosphorylation by p38 kinase could also be activated in re-
sponse to oxidative stress and that this may regulate GSK3
activity [67]. Also, other proteins like cdk5 may regulate
GSK3 activity [68].6. Aging and GSK3 activation
As previously indicated, aging is one of the main risk factors
for AD. Almost all CNS neurons are of the same age as the
organism in which they are found, and aged neurons are more
susceptible than younger ones to increasing concentrations of
glutamate. Hence, attempts are being made to slow down the
progression of AD with a weak NMDA antagonist, meman-
tine [69]. It was recently proposed [70] that glutamate toxicity
could facilitate the activation of NMDA receptors, an increase
in intracellular calcium and calpain activation, as well as the
cleavage of GSK3 that could activate this kinase [70]. Alterna-
tively, an increase in GSK3 immunoreactivity with age has
been reported in the CNS of rats [71]. Thus, GSK3 activation
could be a common feature of familiae and sporadic AD,
implicated in the formation of SP and NFT, as well as in neu-
ron death, particularly since GSK3 overexpression may result
in neuron death [7].7. The spreading of tau pathology
The development of AD in diﬀerent brain regions appears to
somehow follow the spreading of the tau pathology [32,72]
(evident through the aggregation of tau and its phosphoryla-
tion at sites modiﬁed by GSK3), and cell death. These patho-
logical changes commence in the transentorhinal/entorhinal
region, and they spread to the hippocampus and the limbic re-
gions and ﬁnally, similar damage is found in diﬀerent cortical
regions.
It is well known, that there are memory deﬁcits at earlier
stages of the disease, which could be related to the damage
in the hippocampus, while the dementia that appears at later
stages, could be related to damage in the cortex. In terms of
the initial damage found in the entorhinal cortex (upper lay-ers), expression of a FAD-linked presenilin 1 variant induces
neuronal loss in these layers [73]. A decrease in the number
of cells expressing reelin in regions like the entorhinal cortex
(layers I and II) and hippocampus is also associated with
aging, and this decrease could be due to the formation of
amyloid-like reelin aggregates that may further stimulate the
formation of Ab oligomers [74]. Reelin signaling can down reg-
ulate GSK3 activity [75–77] and thus, the formation of these
oligomers or the decrease in reelin could augment GSK3 acti-
vation. To mimic this situation, a GSK3 transgenic mouse was
generated that mainly overexpresses the kinase in the hippo-
campus and cortex [7]. One consequence of GSK3 overexpres-
sion in this model was a decrease in the volume of the dentate
gyrus (DG) as a result of its degeneration [78]. One important
characteristic of the DG is the existence of neurogenesis, a pro-
cess that diminishes during aging [79,80]. Neurogenesis in the
DG produces newborn neurons that are integrated into func-
tional neural networks [81] through the formation of synapses
[82]. These new neurons may be important in hippocampal-
dependent learning [82]. Thus, degeneration in that area could
be correlated with memory deﬁcits and such eﬀects may possi-
bly be corrected with transplants of neuronal precursor cells
[83]. In addition, it has been suggested [8] that up regulation
of GSK3 activity could provoke the death of neuronal
precursors (S. Siresol, P. Go´mez-Ramos, F. H., M. Pe´rez,
M.A. Mora´n, J.J. Lucas, J. A., J.M. Garcı´a Verdugo to be
published) and microglia activation, which in turn may induce
the aberrant proliferation and diﬀerentiation of those precur-
sors [84], a phenomenon thought to be associated with AD
[85,86].
A consequence of cell death is that intracellular components
are released into the extracellular space where they may be
toxic to the surrounding cells. It has been proposed that extra-
cellular tau may be toxic and that it could promote the death
of neighboring neurons; after binding of extracellular tau to
muscarinic receptors of neighboring neurons [8,87]. This mech-
anism has been suggested as a possible way by which the tau
pathology can spread to the hippocampus [87,88], although
whether it participates in the further spreading of the
pathology to the cortex, where dementia commences, should
be analyzed.8. The GSK3 hypothesis of Alzheimers disease
Recently, in an article published with this very same title
[89], it was proposed that the over activity of GSK3 accounts
for memory impairment, tau phosphorylation, increased amy-
loid production and microglia-mediated inﬂammation, all fea-
tures of AD. It was also suggested that GSK3 might be a link
between the amyloid and tau pathology [90]. In a diﬀerent but
complementary way, we might consider whether changes in
GSK3 activity could account for the changes in tau that are
found in AD and tau pathologies [32,72]. Tau pathology ﬁrst
develops in the entorhinal cortex, probably in layer II where
the stellate neurons are found [32] (Fig. 1A). In that layer, little
is known about the possible diﬀerences in the GSK3 signaling
pathways between these stellate cells and the pyramidal cells
found in other layers or hippocampal regions. On the other
hand, the expression of a FAD-linked presenilin I variant in




































Fig. 1. Common features in the diﬀerent types of AD include the site of disease onset, GSK3 activation and development of tau pathology. (A) The
disease initiates in the entorhinal/hippocampal regions, much interest having been focused on the degeneration in layer II of the entorhinal cortex (1).
Then, it could be spread to other regions (dentate gyrus, CA3, CA1, . . .) (2–7). In this degeneration, proteins like PS1, GSK3, or reelin, may play an
important role (see Section 8). (B) Once neurodegeneration takes place it could spread to other neurons, in part due to the accumulation of tau in the
extracellular space after neuron death. (d) indicates tau molecules. This extracellular tau could be toxic for the surrounding neurons upon binding to
their muscarinic receptors (h) (see text). (C) Some aspects of tau pathologies, like its hyperphosphorylation, may be the consequence, at least in the
cortex, of GSK3 activation by beta-amyloid oligomers that arise (in FAD) mainly due to the increase of c secretase activity of mutated PS-1 (see text)
(d) indicates unmodiﬁed tau, whereas () indicates hyperphosphorylated tau. The presence of phosphotau could be toxic to the neuron that may
then degenerate.
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in GSK3 activity in layer II of the EC may be correlated with
cell aging through the changes in reelin levels that take place
speciﬁcally in that region [74]. Thus, GSK3 activation in layer
II may provoke neurodegeneration. EC layer II neurons con-
nect with the dentate gyrus through electrical signals, and elec-trical activity inﬂuences hippocampal neurogenesis in the
subgranular zone of the adult dentate gyrus [91]. GSK3 may
play a role in the neurogenesis in that region, since increased
GSK3 activity could inﬂuence the proliferation and diﬀerenti-
ation of newborn neurons (S. Siresol, P.Go´mez-Ramos, F. H.,
M. Pe´rez, M.A. Mora´n, J.J. Lucas, J. A., J.M. Garcı´a Verdugo
3852 F. Herna´ndez, J. Avila / FEBS Letters 582 (2008) 3848–3854to be published) (see also [92,93]), and such an eﬀect may pro-
voke defects in the connections that are involved in memory
formation (Fig. 1A) [94]. The consequences of any such defects
will be an impairment of memory, a well known feature of AD.
Neurodegeneration may also be a consequence of altering
the maturation of newborn neurons and the associated release
of intracellular components might establish a sort of positive
feedback loop that results in cell death and the spreading of
tau pathology by the mechanisms indicated above (Fig. 1C)
[87,88]. Alternatively, in brain regions like the cortex, muta-
tions in APP or PS-1 may result in FAD, and they may pro-
voke an increase in GSK3 activity that will facilitate tau
phosphorylation and probably, cell toxicity (Fig. 1B) [72].
The death of cortical neurons will result in the appearance of
dementia, being the deﬁnition of dementia: the loss of intellec-
tual abilities that is severe enough to interfere with social or
occupational functioning. It involves language and behavioral
disturbances associated with frontal lobe atrophy, or with def-
icits in visuospatial function and performance of over-learned
tasks, functions of the parietal lobe [95]. Much work should be
done to analyze if there is a role for GSK3 in cortex neurons in
this stage (dementia) of the disease, similar to that found in
hippocampal neurons.
In summary, in addition to the well known hallmarks of Alz-
heimers disease, such as SP, NFT or neuron death, there are
some common features that are shared by Familial and Spo-
radic AD. These phenomena include the common localization
of the origin of the disease and the activation of the GSK3 pro-
tein kinase, in the early stages of the disease. Although these
features have yet to receive the attention given to the more
classical hallmarks of AD, they could serve as useful markers
for the early diagnosis of the disease or provide important no-
vel therapeutic targets.
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